3 Halal Healthcare Dividend Stocks

 

During the current bear market, one of the outperforming sectors is healthcare. Here are 3 Halal Healthcare stocks with attractive dividend yields and are currently outperforming the markets.

1. Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company that is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer Health segment includes a range of products that is focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health, and wound care markets. The Pharmaceutical segment is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism, and Pulmonary Hypertension. The Medical Devices segment includes a range of products used in the interventional solutions, orthopedics, surgery, and vision fields. It is listed on the NYSE and is a component of both the S&P 500 and the Dow Jones.

JNJ has a PE ratio of around 24 and a healthy dividend yield of around 2.5 percent.

Analysts currently have an average price target of 183.8 for the next 12 months with a low price target of 160 and a high target of 210. It currently has a recommendation rating of 2.4 or a ‘BUY’. 

JNJ has seen steady and healthy revenue and earnings growth over the past 4 years and has beaten analyst earnings expectations in the past 4 out of 4 quarters.

 

 

2. AbbVie (ABBV)

AbbVie is a research-based bio-pharmaceutical company that develops and sells pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011, and was listed on the NYSE in 2013. It is a spin-off of Abbot Laboratories. It is a component of the S&P 500.

AbbVie has a PE ratio of around 20 and a high dividend yield of around 4 percent. 

Analysts currently have an average price target of 158.6 for the next 12 months with a low price target of 130 and a high target of 200. It currently has a recommendation rating of 2.2 or a ‘BUY’. 

 

AbbVie has beaten analyst earnings expectations in the past 3 out of 4 quarters. Revenue has been increasing steadily for the past 4 years and earnings are also higher than in 2018.

3. Merck & Co (MRK)

Merck & Co is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biological therapies, and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes health pharmaceutical and vaccine products. The Animal Health segment develops, manufactures, and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment, and control of disease in all livestock and companion animal species. It is listed on the NYSE and is a component of both the S&P 500 and the Dow Jones.

Merck has a PE ratio of around 15 and a high dividend yield of around 3 percent. Analysts currently have an average price target of 106.64 for the next 12 months with a low price target of 85 and a high target of 125. It currently has a recommendation rating of 2.2 or ‘BUY’. 

Merck has beaten analyst earnings expectations in the past 4 out of 4 quarters. Merck’s revenue and earnings both have increased over the past 4 years.

Disclaimer: This post is not financial advice nor is it meant to be. Consult a financial advisor before making investments of any sort. The companies mentioned above were verified to shariah complaint through the Zoya App on 1/11/2022. WE are not shariah advisors nor do we have a fatwa regarding the compliance of the above mentioned companies.